Palavras-chave
Leishmaniose visceral
Hanseníase
IgM anti-PGL1
Agência de Fomento: CNPQ
Hanseníase
IgM anti-PGL1
Agência de Fomento: CNPQ
Como Citar
1.
Carneiro IPDM, Macedo AC de, Nagao-Dias AT, Henn GA de L, Campelo CM, Pinto LCA, Câmara LMC. Estudo sorológico da co-infecção de leishmania infantum e mycobacterium leprae em área de alta endemicidade. Hansen. Int. [Internet]. 30º de novembro de 2015 [citado 9º de maio de 2025];40(2):59-64. Disponível em: https://periodicos.saude.sp.gov.br/hansenologia/article/view/36176
Resumo
Introdução: A região Nordeste é responsável por 55% dos casos de hanseníase e por quase 50% dos casos de Leishmaniose visceral no Brasil. O Ceará, em especial a capital Fortaleza, é responsável por um grande número de casos novos dessas doenças. Este fato é reforçado pela correlação na distribuição de casos dessas patologias por municípios do estado do Ceará, onde de acordo com os dados da Secretaria de Saúde do Estado (2013), observa-se forte correlação epidemiológica entre os casos de hanseníase e do Leishmaniose visceral nos 184 municípios principalmente em Fortaleza. Objetivos: Nosso objetivo foi analisar a produção de anticorpos IgM anti-PGL1 em pacientes com Calazar sem tratamento.Material e métodos: 28 pacientes com confirmação clínico-laboratorial para Leishmaniose visceral acompanhados no Hospital São José de Doenças Infecciosas. Resultados: Quanto ao gênero, 21 foram do sexo masculino e 7 do sexo feminino, com mediana de idade de 20,5 anos (var. 3 a 76 anos), dos quais 15 pacientes não necessitaram internamento e 13 foram internados por um período médio de 28 dias (var. 5 a 28 dias). A média e desvio-padrão do índice de IgM anti-PGL1 foi de 1,91 + 0,69, sendo 78,6% considerados soropositivos. Conclusão: Não foi observada qualquer diferençaentre gênero, idade, necessidade ou não de internamento, ou tempo de tratamento. A alta frequência de IgM anti-PGL1 positiva pode ser secundária à ativiação policlonal que ocorre na Leishmaniose visceral, dificultando a possibilidade de detecção da infecção pelo M. lepraepor avaliação sorológica em região de alta endemicidade para Leishmaniose visceral.
Referências
1 Hawley DM, Altizer SM. Disease ecology meets ecological immunology understanding the links between organismal immunity and infection dynamics in natural populations. Funct Ecol. 2011;25(1):48-60. doi: 10.1111/j.1365-2435.2010.01753.x
2 Ezenwa OV, Jolles EA. From host immunity to pathogen invasion: the effects of helmint coinfection on the dynamics of microparasites. Integr Comp Biol. 2011;51(4):540-551. doi: 10.1093/icb/icr058
3 Lee NH, Embi CS, Vigeland KM, White CR Jr. Concomitant pulmonary tuberculosis and leprosy. J Am Acad Dermatol. 2003 Oct;49(4):755-7. doi:10.1067/S0190-9622(03)00456-0
4 Supali T, Verweij JJ, Wiria AE, Djuardi Y, Hamid F, Kaisar MMM, et al. Polyparasitismand its impact on the immune system. Int J Parasitol. 2010 Aug;40(10):1171-6. doi:10.1016/j.ijpara.2010.05.003
5 Wammes LJ, Hamid F, Wiria AE, Gier B, Sartono E, Maizels RM, et al. Regulatory T cells in human geohelminth infection suppress immune responses to BCG and Plasmodium falciparum. Eur J Immunol. 2010;40(2):437-42. doi:10.1002/eji.200939699
6 Delobel P,Launois P, Djossou F, Sainte-Marie D, Pradinaud R. American cutaneous leishmaniasis, lepromatous lepros and pulmonary tuberculosis coinfection with downregulation of the T-helper 1 cell response. Clin Infect Dis. 2003;37(5):628-33. doi: 10.1086/376632
7 Molina I, Fisa R, Riera C, Falcó V, Elizalde A, Salvador F, et al. Ultrasensitive Real-Time PCR for the clinical management of visceral lesihmaniasis in HIV-infected patients. Am J Trop Hyg. 2013;89(1):105-10. doi:10.4269/ajtmh.12-0527
8 Bogaart EVD, Talha AB, Straetemans M, Mens PF, Adams ER, Grobusch MP et al. Cytokine profiles amongst Sudanese patients with visceral leishmaniasis and malaria co-infections. BMC Immunol. 2014 May;15(16):1-10. doi: 10.1186/1471-21721516
9 Scollard DM, Stryjewska BM, Prestigiacomo JF, Gillis TP, Waguespack-Labiche J. Hansen’s disease (leprosy) complicated by secondary mycobacterial infection. J Am Acad Dermatol. 2011 Mar;64(3):593-6. doi: 10.1016/j.jaad.2009.10.004.
10 Rijal A, Rijal S, Bhandari S. Leprosy coinfection with kala-zar.Int J Dermatol. 2009 Jul;48(7):740-2. doi:10.1111/j.1365-4632.2009.04018.x.
11 Azeredo-Coutinho RBG, Matos DCS, Nery JAC, Valete-RosalinoVM, Mendonça SCF. Interleikin-10 dependent down regulation of inteferon-gamma response to Leishmania by Mycobacterium leprae antigens during the clinical course of a coinfection. Braz J Med Biol Res 2012 July;45(7):632-6. doi:10.1590/S0100-879X2012007500073
12 Cecílio P, Pérez-Cabezas B, Santarém N, Maciel J, Rodrigues V, Cordeiro da Silva A. Deception and manipulation: the arms of Leishmania, a successful parasite. Front Immunol. 2014 Oct 20;5:480. doi: 10.3389/fimmu.2014.00480
13 Zofou D, Nyasa RB, Nsagha DS, Ntie-Kang F, Meriki HD, Assob JC, et al. Control of malaria and other vector-borne protozoan diseases in the tropics: enduring challenges despite considerable progress and achievements. Infect Dis Poverty. 2014 Jan 8;3(1):1. doi: 10.1186/2049-9957-3-1
14 Clem A. A current perspective on leishmaniasis. J Glob Infect Dis. 2010 May;2(2):124-6. doi: 10.4103/0974-777X.62863.
15 Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7(5):e35671. doi: 10.1371/journal.pone.0035671.
16 Gross TJ1, Kremens K, Powers LS, Brink B, Knutson T, Domann FE et al. Epigenetic silencing of the human NOS2 gene: rethinking the role of nitric oxide in human macrophage inflammatory responses. J Immunol. 2014 Mar 1;192(5):2326-38. doi: 10.4049/jimmunol.1301758
17 Olivier M, Atayde VD, Isnard A, Hassani K, Shio MT. Leishmania virulence factors: focus on the metalloprotease GP63. Microbes Infect. 2012 Dec;14(15):1377-89. doi: 10.1016/j.micinf.2012.05.014
18 Stromme EM, Bærøe K, Norheim OF. Disease control priorities for neglected tropical diseases: lessons form priority ranking based on the quality of evidence, cost effectiveness, severity of disease, catastrophic health expenditures, and loss of productivity. Dev World Bioeth. 2014;14(3):132-41. doi:10.1111/dewb.12016
19 Boer MC, Joosten SA, Ottenhoff TH. Regulatory T-cells at the interface between human host and pathogens in infectious diseases and vaccination.Front Immunol. 2015 May 11;6:217. doi: 10.3389/fimmu.2015.00217.
20 Roy S, Mukhopadhyay D, Mukherjee S, Ghosh S, Kumar S, Sarkar K, et al. A defective oxidative burst and impaired antigen presentation are hallmarks of human visceral leishmaniasis. J Clin Immunol. 2015 Jan;35(1):56-67. doi: 10.1007/s10875-014-0115-3.
21 Nagao-dias AT, Almeida TLP, Oliveira MF, Santos RC, Lima ALP, Brasil M. Salivary anti-PGL IgM and IgA titers and serum antibody IgG titers and avidities in leprosy patients and their correlation with time of infection and antigen exposure. Braz J Infect Dis. 2007 Apr;11(2):215-9. doi:101590/S1413-86702007000200009
22 Foss NT, Callera F, Alberto FL. Anti-PGL1 levels in leprosy patients and their contacts. Braz J Med Biol. 1993 [cited 2015 Nov 20];26(1):43-51 Available from: http://www.ncbi.nlm.nih.gov/pubmed/8220267
23 Frota CC, Freitas MV, Foss NT, Lima LN, Rodrigues LC, Barreto ML, et al. Seropositivity to anti-phenolic glycolipid-I in leprosy cases, contacts and no known contacts od leprosy in an endemic and a non-endemic area in Northeast Brazil. Trans R Soc Trop Med Hyg. 2010 Jul;104(7):490-5. doi: 10.1016/j.trstmh.2010.03.006.
24 Bazan-furini R, Motta ACF, Simão JCL, Tarquinio DC, Marques W Junior, Barbosa MHN et al. Early detection of leprosy by examination of household contects, determination of serun anti-PGL1 antibodies and consanguinity. Mem Ins Oswaldo Cruz. 2011;106(5):536-40. doi: 10.1590/S0074-02762011000500003
25 Amezcua Vesely MC, Bermejo DA, Montes CL, Acosta-Rodríguez EV, Gruppi A. B-cell response during protozoan parasite infections. J Parasitol Res. 2012;2012:362131. doi: 10.1155/2012/362131.
2 Ezenwa OV, Jolles EA. From host immunity to pathogen invasion: the effects of helmint coinfection on the dynamics of microparasites. Integr Comp Biol. 2011;51(4):540-551. doi: 10.1093/icb/icr058
3 Lee NH, Embi CS, Vigeland KM, White CR Jr. Concomitant pulmonary tuberculosis and leprosy. J Am Acad Dermatol. 2003 Oct;49(4):755-7. doi:10.1067/S0190-9622(03)00456-0
4 Supali T, Verweij JJ, Wiria AE, Djuardi Y, Hamid F, Kaisar MMM, et al. Polyparasitismand its impact on the immune system. Int J Parasitol. 2010 Aug;40(10):1171-6. doi:10.1016/j.ijpara.2010.05.003
5 Wammes LJ, Hamid F, Wiria AE, Gier B, Sartono E, Maizels RM, et al. Regulatory T cells in human geohelminth infection suppress immune responses to BCG and Plasmodium falciparum. Eur J Immunol. 2010;40(2):437-42. doi:10.1002/eji.200939699
6 Delobel P,Launois P, Djossou F, Sainte-Marie D, Pradinaud R. American cutaneous leishmaniasis, lepromatous lepros and pulmonary tuberculosis coinfection with downregulation of the T-helper 1 cell response. Clin Infect Dis. 2003;37(5):628-33. doi: 10.1086/376632
7 Molina I, Fisa R, Riera C, Falcó V, Elizalde A, Salvador F, et al. Ultrasensitive Real-Time PCR for the clinical management of visceral lesihmaniasis in HIV-infected patients. Am J Trop Hyg. 2013;89(1):105-10. doi:10.4269/ajtmh.12-0527
8 Bogaart EVD, Talha AB, Straetemans M, Mens PF, Adams ER, Grobusch MP et al. Cytokine profiles amongst Sudanese patients with visceral leishmaniasis and malaria co-infections. BMC Immunol. 2014 May;15(16):1-10. doi: 10.1186/1471-21721516
9 Scollard DM, Stryjewska BM, Prestigiacomo JF, Gillis TP, Waguespack-Labiche J. Hansen’s disease (leprosy) complicated by secondary mycobacterial infection. J Am Acad Dermatol. 2011 Mar;64(3):593-6. doi: 10.1016/j.jaad.2009.10.004.
10 Rijal A, Rijal S, Bhandari S. Leprosy coinfection with kala-zar.Int J Dermatol. 2009 Jul;48(7):740-2. doi:10.1111/j.1365-4632.2009.04018.x.
11 Azeredo-Coutinho RBG, Matos DCS, Nery JAC, Valete-RosalinoVM, Mendonça SCF. Interleikin-10 dependent down regulation of inteferon-gamma response to Leishmania by Mycobacterium leprae antigens during the clinical course of a coinfection. Braz J Med Biol Res 2012 July;45(7):632-6. doi:10.1590/S0100-879X2012007500073
12 Cecílio P, Pérez-Cabezas B, Santarém N, Maciel J, Rodrigues V, Cordeiro da Silva A. Deception and manipulation: the arms of Leishmania, a successful parasite. Front Immunol. 2014 Oct 20;5:480. doi: 10.3389/fimmu.2014.00480
13 Zofou D, Nyasa RB, Nsagha DS, Ntie-Kang F, Meriki HD, Assob JC, et al. Control of malaria and other vector-borne protozoan diseases in the tropics: enduring challenges despite considerable progress and achievements. Infect Dis Poverty. 2014 Jan 8;3(1):1. doi: 10.1186/2049-9957-3-1
14 Clem A. A current perspective on leishmaniasis. J Glob Infect Dis. 2010 May;2(2):124-6. doi: 10.4103/0974-777X.62863.
15 Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One. 2012;7(5):e35671. doi: 10.1371/journal.pone.0035671.
16 Gross TJ1, Kremens K, Powers LS, Brink B, Knutson T, Domann FE et al. Epigenetic silencing of the human NOS2 gene: rethinking the role of nitric oxide in human macrophage inflammatory responses. J Immunol. 2014 Mar 1;192(5):2326-38. doi: 10.4049/jimmunol.1301758
17 Olivier M, Atayde VD, Isnard A, Hassani K, Shio MT. Leishmania virulence factors: focus on the metalloprotease GP63. Microbes Infect. 2012 Dec;14(15):1377-89. doi: 10.1016/j.micinf.2012.05.014
18 Stromme EM, Bærøe K, Norheim OF. Disease control priorities for neglected tropical diseases: lessons form priority ranking based on the quality of evidence, cost effectiveness, severity of disease, catastrophic health expenditures, and loss of productivity. Dev World Bioeth. 2014;14(3):132-41. doi:10.1111/dewb.12016
19 Boer MC, Joosten SA, Ottenhoff TH. Regulatory T-cells at the interface between human host and pathogens in infectious diseases and vaccination.Front Immunol. 2015 May 11;6:217. doi: 10.3389/fimmu.2015.00217.
20 Roy S, Mukhopadhyay D, Mukherjee S, Ghosh S, Kumar S, Sarkar K, et al. A defective oxidative burst and impaired antigen presentation are hallmarks of human visceral leishmaniasis. J Clin Immunol. 2015 Jan;35(1):56-67. doi: 10.1007/s10875-014-0115-3.
21 Nagao-dias AT, Almeida TLP, Oliveira MF, Santos RC, Lima ALP, Brasil M. Salivary anti-PGL IgM and IgA titers and serum antibody IgG titers and avidities in leprosy patients and their correlation with time of infection and antigen exposure. Braz J Infect Dis. 2007 Apr;11(2):215-9. doi:101590/S1413-86702007000200009
22 Foss NT, Callera F, Alberto FL. Anti-PGL1 levels in leprosy patients and their contacts. Braz J Med Biol. 1993 [cited 2015 Nov 20];26(1):43-51 Available from: http://www.ncbi.nlm.nih.gov/pubmed/8220267
23 Frota CC, Freitas MV, Foss NT, Lima LN, Rodrigues LC, Barreto ML, et al. Seropositivity to anti-phenolic glycolipid-I in leprosy cases, contacts and no known contacts od leprosy in an endemic and a non-endemic area in Northeast Brazil. Trans R Soc Trop Med Hyg. 2010 Jul;104(7):490-5. doi: 10.1016/j.trstmh.2010.03.006.
24 Bazan-furini R, Motta ACF, Simão JCL, Tarquinio DC, Marques W Junior, Barbosa MHN et al. Early detection of leprosy by examination of household contects, determination of serun anti-PGL1 antibodies and consanguinity. Mem Ins Oswaldo Cruz. 2011;106(5):536-40. doi: 10.1590/S0074-02762011000500003
25 Amezcua Vesely MC, Bermejo DA, Montes CL, Acosta-Rodríguez EV, Gruppi A. B-cell response during protozoan parasite infections. J Parasitol Res. 2012;2012:362131. doi: 10.1155/2012/362131.
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Downloads
Não há dados estatísticos.
